By focusing on the development of novel STING agonists, strategic combination therapies, and actionable biomarkers, future research can provide clearer and more targeted solutions for overcoming current limitations in cGAS-STING-targeted cancer immunotherapy. This evidence concerns the gene STING1 and cancer.